Our profiling and comparison of the actions of conolidine and cannabidiol with recognised pharmacological brokers predicted a MOA shared with Cav2.two channel blocker, ω-conotoxin CVIE. Most recently, it has been recognized that conolidine and the above derivatives act within the atypical chemokine receptor 3 (ACKR3. Expressed in very similar https://irvingt147hea6.buscawiki.com/user